SXTP PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

SXTP ▲ +6.47% at T+5d

SHORT call ✗ call lost -6.47% · α vs SPY -5.51% · entry $1.39 → $1.48

Next anchor: T+20d in 5d

Last close $1.43 (close Jun 8) · -2.88% from $1.39 entry (call sign-flipped)

Entry anchored
May 14, 03:59 PM ET
via Databento tick

T+1d

+3.60%

call -3.60% · α -3.66%

$1.44

settled 23d ago

T+5d

+6.47%

call -6.47% · α -5.51%

$1.48

settled 19d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Sixty Degrees Pharmaceuticals reported Q1 2026 revenue of $162K (down ~1% YoY) and a net loss of $1.28 per share, significantly missing the consensus EPS estimate of -$0.99. The company continues to burn cash with operating expenses of $2.17M against minimal revenue, and the going-concern warning in the forward-looking statements underscores persistent financial distress.

Key Financial Metrics

Gross Margin

46.91%

Actionable Insight

The EPS miss and widening net loss reinforce the company's cash-burn trajectory against a negligible revenue base. With a $4M market cap and going-concern risk, the stock is highly speculative and likely to remain under pressure. Monitor for any financing or partnership announcements that could extend the cash runway.

Key Facts

Q1 2026 net product revenue of ~$162K, down ~1% from $164K in Q1 2025
EPS of -$1.28 missed consensus estimate of -$0.99 by 29.3%
Net loss of ~$2.21M vs ~$2.00M in Q1 2025, widening 10.5%
Gross profit fell to ~$76K from $90K in the prior-year quarter
Operating expenses increased to ~$2.17M from ~$2.09M
Going-concern risk reiterated in forward-looking statements

Financial Impact

EPS miss of 29.3% on consensus -$0.99; revenue essentially flat at $162K; net loss widened by ~$210K

revenueepsnet lossgross profit

Risk Factors

Going-concern risk — cash burn exceeds revenue by >10x
No near-term catalyst for revenue inflection
Low market cap ($4M) amplifies volatility and delisting risk

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

88% bullish (8 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3295850

4 reports for SXTP

T+1T+5T+20T+60

Filters

Reports for SXTP — sortable, filterable
	Type				Now
May 26, 2026 14d ago	Press Release NEUTRAL ★ 4/10	$1.50 $1.46	▼ −2.67%	▼ −3.75%	$1.43 (−4.67%)
May 15, 2026 25d ago	Press Release BEARISH ★ 6/10	$1.39 $1.48	▼ −6.47%	▼ −5.51%	$1.43 (−2.88%)
Mar 31, 2026 10w ago	Press Release MIXED ★ 5/10	$1.75 $1.81	▲ +3.43%	▼ −0.52%	$1.43 (−18.29%)
Mar 18, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$2.12 $1.55	▼ −26.89%	▼ −26.17%	$1.43 (−32.55%)

US Market Status

Market Closed — Opens in 8h 59m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access